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ImmunohistochemistryAbstract Small cell lung cancer and extrapulmonary small cell carcinomas are the most
aggressive type of neuroendocrine carcinomas. Clinical treatment relies on conventional che-
motherapy and radiotherapy; relapses are frequent. The PD-1/PD-L1/PD-L2 pathway is a
major target of anti-tumour immunotherapy. Aberrant PD-L1 or PD-L2 expression may
cause local immune-suppression. Here we investigated expression of PD-1 and its ligands
by immunohistochemistry and RNA-seq in small cell carcinomas.
PD-L1 and PD-1 protein expression were analysed in 94 clinical cases of small cell carcinomas
(61 pulmonary, 33 extrapulmonary) by immunohistochemistry using two different monoclo-
nal antibodies (5H1, E1L3N). RNA expression was proﬁled by RNA-seq in 43 clinical cases.
None of the small cell carcinomas showed PD-L1 protein expression in tumour cells. PD-L1
and PD-1 expression was noticed in the stroma: Using immunohistochemistry, 18.5% of cases
(17/92) showed PD-L1 expression in tumour-inﬁltrating macrophages and 48% showed PD-1
positive lymphocytes (45/94). RNA-seq showed moderate PD-L1 gene expression in 37.2%
(16/43). PD-L1 was correlated with macrophage and T-cell markers. The second PD-1 ligand
PD-L2 was expressed in 27.9% (12/43) and showed similar correlations.
Thus, the PD-1/PD-L1 pathway seems activated in a fraction of small cell carcinomas. The
carcinoma cells were negative in all cases, PD-L1 was expressed in tumour-inﬁltrating
macrophages and was correlated with tumour-inﬁltrating lymphocytes. Patients with stromalSA.
422 A.M. Schultheis et al. / European Journal of Cancer 51 (2015) 421–426PD-L1/PD-L2 expression may respond to anti-PD-1 treatment. Thus, evaluation of the
composition of the tumour microenvironment should be included in clinical trials. Besides
conventional immunohistochemistry, RNA-seq seems suitable for detection of PD-L1/PD-
L2 expression and might prove to be more sensitive.
 2014 The Authors. Published by Elsevier Ltd. This is an open access article under the CC
BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Small cell carcinoma is an aggressive neoplasm
thought to be arising from neuroendocrine cells, most
notably in the lung (small cell lung cancer, SCLC).
SCLC represents 13–15% of primary lung cancers [1].
The median survival ranges from 23 months for lim-
ited-stage disease to eight months for extensive-stage
disease [1]. Clinical treatment remained mainly
unchanged for the last three decades and relies on con-
ventional chemotherapy and radiotherapy [2].
A more recent therapeutic strategy is the use of
anti-tumour immunotherapy such as blockade of
co-inhibitory immune pathways, in particular PD-1/
PD-L1. Aberrant activation of co-inhibitory pathways
is a key determent of local immune-suppression, and
counteracting PD-1/PD-L1 was demonstrated to yield
strong and durable tumour regression in several solid
tumours [3,4]. Monoclonal antibodies targeting PD-L1
or PD-1 are currently in phase III clinical trials with ﬁrst
positive results [4] in malignant melanoma, lung
adenocarcinoma, non-Hodgkin lymphoma, renal cell
carcinoma, and triple-negative breast cancer [5–8].
In the context of clinical trials, PD-L1 protein expres-
sion on tumour cells detected by immunohistochemistry
(IHC) is currently the best predictive biomarker [5–8].
However, responses may occur in patients with PD-L1
IHC-negative tumours, and not all PD-L1 positive cases
respond [3,9].
To date, the expression of PD-L1 in SCLC and extra-
pulmonary small cell carcinomas has not been explored.
The aim of this study was to investigate PD-L1 and PD-
1 expression patterns in small cell carcinomas and to
compare conventional IHC with RNA-seq expression
analysis.
2. Patients and methods
2.1. Patients
The study was approved by the local ethics commit-
tee. Informed consent was obtained from each patient.
Clinical treatment was performed in the context of the
molecular diagnostics programme ‘Network Genomic
Medicine’, an academic multi-centre non-proﬁt collabo-
ration based at the Center for Integrated Oncology
Ko¨ln-Bonn (www.ngml.de).2.2. Sample selection and TMA preparation
Cases were selected from the archives of the Institute
of Pathology, University Hospital Cologne, Germany.
Formalin-ﬁxed, paraﬃn-embedded tissue of 61 SCLCs
and 33 extrapulmonary small cell carcinomas, including
45 primary tumours and 49 distant metastases (51 resec-
tion specimens, 43 biopsies), were arranged as tissue
microarrays (Beecher Instruments, Sun Prairie, WI).
Three regions of each paraﬃn-block were sampled with
1 mm core diameter, i.e. 2.36 mm2 tissue per case. Each
microarray contained tonsil-tissue as on-slide positive
control. Thirteen cores containing lung adenocarcino-
mas were included as additional on-slide control.
Primary diagnoses were veriﬁed by three experienced
pathologists (R.B., L.O., A.M.S.) according to current
recommendations [1]: Morphologic features were evalu-
ated on H&E stained slides, and immunohistochemical
standard markers were used in each case (except for
three cases in which the paraﬃn blocks were exhausted):
Neuroendocrine markers (Chromogranin A, Synapto-
physin, CD56, Neuron-Speciﬁc Enolase), Cytokeratins
(Pancytokeratin AE1/AE3 or CK7), Ki-67 and TTF1.
Cases were selected if positive for one or more neuroen-
docrine markers, and if the Ki-67 labeling index was
P60% [10]. Eighty-seven samples (98%) were positive
for cytokeratins. Information on the clinical cases are
summarised in Supplementary Table 1.
2.3. Immunohistochemistry
PD-L1 immunohistochemistry was performed with
either the non-commercial mouse monoclonal antibody
5H1 (kindly provided by Lieping Chen’s laboratory,
Yale University, USA), or the commercial rabbit mono-
clonal antibody E1L3N (Cell Signaling Technology,
Cambridge, UK). Both antibodies yielded similar stain-
ing patterns and intensities (Supplementary Fig. 1). For
PD-1 mouse monoclonal antibody NAT105 (Abcam,
Cambridge, UK) was used. Detection was performed
on an automated staining system with polymer-based
secondary antibody kit and DAB (Leica Bond Polymer
Reﬁne; Leica Biosystems, Wetzlar, Germany) (Repre-
sentative microphotographs: Supplementary Fig. 2).
Routine diagnostic immunohistochemistry was per-
formed on an automated staining system according to
standardised protocols (Leica Bond).
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L.O.) scored PD-L1 and PD-1 protein expression in
analogy to the semiquantitative Allred system [11]:
Intensity subdivided into four categories (0–3), propor-
tion of PD-L1 positive cells subdivided into six catego-
ries (0–5), both values added to yield the Allred-Score
(i.e. 0–8). Positivity of the individual cell was deﬁned
to be a circular membranous staining pattern. Occa-
sional cytoplasmatic staining was considered unspeciﬁc
and not scored. Tumour cells and adjacent stroma were
scored separately. The stroma was subdivided into three
regions: inﬁltrating cells within the carcinoma tissue, the
tumour–stroma interface, and the stroma (Supplemen-
tary Table 2). No categorical diﬀerences in staining
intensity and proportions were noticed among the three
experiments.
2.4. RNA-seq data analysis
RNA-seq mRNA expression data are derived from
two recent studies on SCLC. [12,13]. Forty-three resected
primary SCLC cases and 22 SCLC cell lines were
re-analysed in the current study. Paired-end RNA-seq
data were processed as previously described. In brief,Fig. 1. PD-1 and PD-L1 are expressed in the tumour stroma of small ce
extrapulmonary small cell carcinomas (B) did not show any PD-L1 staini
magniﬁcation, scalebar = 100 lm). However, PD-L1 is expressed in tumour
positive T-lymphocytes were noticed in 48% of cases (E); lymphocytes reaRNA-seq reads were aligned to the human reference gen-
ome (hg19). The transcriptional levels of annotated genes
or exons were estimated with cuﬄinks and represented as
FPKM (Fragments Per Kilobase of transcript per
Million mapped reads). The maximal gene expression
was chosen for those genes with multiple splice variants.
2.5. Statistical analysis
Statistics were performed using SPSS analytical soft-
ware (IBM). IHC data were tested by v2 tests with
a = 5%. Correlations were quantiﬁed by Spearman’s
rank correlation coeﬃcient (q). RNA-seq data were
tested by Wilcoxon rank-sum tests. Alpha was adjusted
according to the Bonferroni method to a = 5% * 1/n to
correct for the cumulative error of multiple testing.
3. Results
3.1. PD-L1 protein expression in small cell
neuroendocrine carcinomas
Immunohistochemistry for PD-L1 protein expression
was performed in three separate experiments (antibodyll carcinomas. 94 cases of pulmonary small cell carcinomas (A) and
ng in immunohistochemistry (representative microphotographs, 220
-associated macrophages (C), which stain positive for CD68 (D). PD-1
cted positive for CD3 epsilon (F).
Table 1
Summary of Small Cell Cancer Specimens and IHC PD-1/PD-L1. (A)
Summary of the tissue samples analysed. Ninety-four specimens of
small cell neuroendocrine carcinomas were analysed on tissue micro-
arrays. The samples included pulmonary and extrapulmonary
tumours, primary tumours and metastases. Both resection and biopsy
materials were included. (B) Summary of PD-1 and PD-L1 protein
expression as determined by immunohistochemistry. None of the
tumours showed PD-L1 or PD-1 protein expression. However,
expression of both proteins was found in the stroma.
n (%)
A
Sample Pulmonary 61 (65%)
Extrapulmonary 33 (35%)
Total 94
Origin Primary 45 (48%)
Metastasis 49 (52%)
Total 94
Specimen Resection 51 (54%)
Biopsy 43 (46%)
Total 94
PD-1 PD-L1
Tumour Stroma Tumour Stroma
B
Cases 94 94 Cases 92 92
Positive 0 45 Positive 0 17
% 0.0% 47.9% 0 0.0% 18.5%
q(PD-1, PD-L1): 0, 35.
Fig. 2. RNA expression of PD-1, PD-L1 and PD-L2 in 43 clinical small c
expression displayed as Fragments Per Kilobase of transcript per Million m
the monocyte marker CD68 (B), as well as the common T-lymphocyte gene
Subdividing the samples by PD-L1 expression into high (FPKMP 1.5, exp
the indicated genes (*). Expression of PD-L1 was not related to proliferati
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lung cancers and extrapulmonary small cell carcinomas
stained positive for PD-L1 (Fig. 1A, B; Table 1). The
on-slide positive control showed the expected membra-
nous pattern in the stratiﬁed tonsil epithelium in each
staining (SI Fig. 2), and eight of the 13 spiked-in adeno-
carcinomas were positive (Allred scores 4–7; SI Table 2).
No diﬀerences in intensity were noticed between the two
diﬀerent PD-L1 antibodies.
While the neoplastic cells were completely negative,
18.5% of the cases showed PD-L1 positive cells in the
adjacent stroma (17/92): Cells with monocytic morphol-
ogy located at the interface between neoplastic cells and
desmoplastic stroma showed faint to moderate (intensity
scores 1 or 2) circular membranous staining patterns
(Fig. 1C). These cells were positive for the monocyte/
macrophage IHC-marker CD68 (Fig. 1D) and were con-
sidered tumour-associated macrophages (TAMs).
The cases were subdivided by localisation of the
primary tumour, origin of the tissue, and type of
material (SI Table 3). No major diﬀerences were noticed
among the subgroups, except for origin of the tissue:
13 of 17 cases with stromal PD-L1 expression were
distant metastases, marking a signiﬁcant enrichment
(p = 0.034).ell lung cancer (SCLC) cases and 22 SCLC cell lines (A) (Normalised
apped reads, FPKM). Correlations were noticed between PD-L1 and
CD3E (encoding the epsilon chain of the CD3 receptor complex) (C).
ressed) and low (<1.5, not expressed) showed signiﬁcant diﬀerences in
on-related gene MKI67 (D).
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carcinomas
The tissue microarrays were stained for PD-1
protein expression in a separate experiment. Again,
on-slide tonsil tissue served as positive control (SI
Fig. 2).
Variable levels of tumour-inﬁltrating lymphocytes
(TILs) were noticed and 48% cases (45/94) showed
PD-1 positive TILs (Fig. 1E, F; SI Tables 2 and 3).
The staining intensity was usually moderate (intensity
2) and the TILs were most frequently located at the
interface between carcinoma cells and stroma. Few cases
showed TILs located between the carcinoma cells. The
TILs were positive for CD3 (epsilon chain). Correlations
between PD-L1+ TAMs and PD-1+ TILs were noticed;
among all cases the correlation was 0.35 (Spearman’s
rho) and ranged from 0.21 (primary carcinomas) to
0.56 (extrapulmonary carcinomas) in the subgroups
(SI Table 3).
3.3. PD-L1, PD-L2 and PD-1 gene expression
RNA-seq expression data were analysed in a set of 43
primary SCLCs. Transcript levels of the PD-1 receptor
and its ligands PD-L1 and PD-L2 were not highly abun-
dant, with most samples revealing low or almost no
expression (FPKM < 1.5). However, 23% (10/43) of
the samples showed moderate PD-1 mRNA expression
levels (FPKM > 1.5), while PD-L1 and PD-L2 were
expressed in 37% (16/43) and 28% (12/43), respectively
(Fig. 2A; Supplementary Fig. 3A, Supplementary Tables
4 and 5). Subdividing the samples by PD-L1 expression
into PD-L1 high (FPKM > 1.5; expressed) and low
(FPKM < 1.5, relating to almost no expression) showed
diﬀerences in expression of the macrophage marker
genes CD68 (Fig. 2B), CD163, CD11c and CSF1R (SI
Fig. 3), and the common T-lymphocyte marker (epsilon
chain) (Fig. 2C). This was similarly observed for PD-L2
and PD-1 (SI Fig. 3). The diﬀerences were signiﬁcant in
Wilcoxon-tests adjusted by the Bonferroni-method for
multiple testing (p < 0.05x(1/11) = 0.0045). PD-1/PD-
L1/PD-L2 expression was not associated with diﬀer-
ences in the proliferation-related gene MKI67 (which
corresponds to Ki-67 in IHC) (Fig. 2D, SI Fig. 3B).
Twenty-two SCLC cell lines were likewise analysed
and no expression of the investigated genes was noticed
with two exceptions: CD68 was expressed in 36% (8/22)
cell lines, and NCI_H196 cells were found to express
PD-L2 (Fig. 2, SI Fig. 3, SI Table 5).
In four of the RNA-seq samples, suﬃcient tissue was
available for IHC. IHC for PD-L1 was supplemented,
and no protein expression was noticed in the neoplastic
cells in all four cases. However PD-L1 positivity was
noticed in monocytic cells in the stroma of two of the
cases (data not shown).4. Discussion
Tissue microarrays with 94 cases of SCLC and extra-
pulmonary small cell carcinomas were analysed by
immunohistochemistry (IHC) for expression of PD-L1.
Unexpectedly, none of the tumours showed PD-L1 pro-
tein expression in the tumour cells. However, expression
of PD-L1 was noticed on tumour-associated macro-
phages (TAMs), while tumour-inﬁltrating lymphocytes
(TILs) were positive for PD-1. Consistently, mRNA
expression of PD-L1 and PD-L2 was detected in associ-
ation of macrophage and T-cell markers by RNA-seq.
The success of blocking co-inhibitory pathways has
sparked new interest in anti-tumour immunotherapy.
Many solid tumours were found to express the B7-pro-
tein PD-L1 [7], which interacts with the PD-1 receptor
and causes T-cell anergy. In non-small cell lung cancer,
PD-L1 expression was found in up to 40% of cases [14].
Our study is the ﬁrst to investigate PD-L1 in small cell
lung cancer (SCLC).
A common clinical course of disease in SCLC is good
initial response to chemoradiotherapy, followed by
relapse few months later. The end of chemoradiotherapy
might be a window of opportunity for consecutive
immunotherapy. Chemotherapy stimulates anti-tumour
immune response [15], and an additional boost by
immunotherapeutics might help eradicate residual
tumour cells, increasing the duration of the remission.
On the other hand, immunologic paraneoplastic syn-
dromes are not uncommon in SCLC [16]. It might be
sensible to screen for SCLC-associated autoantibodies
in possible clinical trials to reduce the risk of adverse
eﬀects. Of importance, brain metastases from SCLC
are frequent and require immunosuppressive corticoste-
roids for management, which might interfere with
immunotherapies. In clinical trials with PD-1/PD-L1
inhibitors some patients responded with strong
tumour-regression and excellent outcomes, while others
failed to respond [3–8]. Many parameters of the neoplas-
tic tissue and peripheral blood were tested for their pre-
dictive value to develop companion diagnostic tests for
the new drugs. Currently PD-L1 expression on the
tumour cells is the best predictive marker [8], however,
the test characteristics (sensitivity, speciﬁcity) of PD-
L1 IHC have not been evaluated comprehensively.
In our small cell carcinoma cases no PD-L1 expres-
sion was found on the neoplastic cells, and the cases
would be classiﬁed ‘negative’ along this line. However,
the presence of PD-L1+ TAMs and PD-1+ TILs indi-
cates that the pathway may be activated in 20–35% of
cases: PD-1 is expressed on CD4+ and CD8+ T-lympho-
cytes upon antigen receptor signalling [16].
The PD-L1/PD-1 correlation is in concordance with
a recent study by Taube et al., which demonstrated a
geographic association between PD-L1 expression and
the presence of PD-1+ TILs in ﬁve diﬀerent types of
426 A.M. Schultheis et al. / European Journal of Cancer 51 (2015) 421–426solid tumours [8]. Taube et al. showed that both PD-L1
expression in tumour cells, and the presence of PD-1+
TILs, have predictive value for anti-PD-1 therapy.
We would like to suggest the hypothesis that patients
with small cell carcinoma and stromal PD-L1/PD-L2
expression might respond to anti-PD-1 therapy. Clinical
trials should include a celltype-speciﬁc analysis of the
tumour microenvironment to investigate the signiﬁcance
of PD-L1 expression in tumour-associated cells.
Response to anti-PD-L1 therapy seems less likely given
that PD-L2 might still activate PD-1.
RNA-seq and IHC yielded highly comparable results
in the present study. Using IHC, macrophages as origin
of the PD-L1 expression could be directly observed. In
RNA-seq PD-L1 and PD-L2 mRNA expression was
correlated to macrophage and T-cell expression signa-
tures. RNA-seq of 22 SCLC cell lines conﬁrmed that
the employed marker genes are not expressed by SCLC
and can be attributed to cells in the stroma of the
tumour tissue (except for CD68). RNA-seq yielded more
PD-L1 positive cases than immunohistochemistry
(35.7% versus 18.5% of cases). The result is not surpris-
ing given that tissue microarrays were used for IHC,
while RNA-seq was performed on larger tumour sec-
tions of resection specimens. TAMs and TILs often
show heterogeneous distributions in and around the
neoplastic tissue and might be underrepresented in tissue
microarrays. Furthermore, the sequencing depth yielded
by RNA-seq might be more sensitive than conventional
IHC. Thus, guided by the knowledge of IHC-protein
expression patterns, RNA-seq or similar high-through-
put techniques might be used to screen for PD-L1
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